Business context and reporting period
This unaudited Form 10-Q covers the quarter and six months ended June 30, 2012. The filing identifies the registrant as Ventrus BioSciences, Inc., a development-stage specialty pharmaceutical company focused on gastrointestinal disorders; this differs from the “ASSEMBLY BIOSCIENCES, INC.” company name in the request metadata. Ventrus had no product sales or FDA-approved products.
Financial performance and position
- Revenue: No product revenue was reported.
- Second-quarter results: Research and development expense was $6.16 million, general and administrative expense was $1.32 million, and net loss was $7.47 million, or $0.59 per share.
- First-half results: Research and development expense was $12.58 million, general and administrative expense was $3.08 million, and net loss was $15.64 million, or $1.25 per share.
- Cash flow: First-half operating cash use was $13.03 million; investing cash use was $3,240; financing provided $4.90 million. Cash and cash equivalents declined by $8.13 million to $28.84 million at June 30.
- Liquidity and debt: Current assets were $29.00 million and current liabilities were $3.39 million. The company reported no outstanding loans during the first half of 2012. It said existing cash was expected to fund operations and planned development through the third quarter of 2014.
- Other balance-sheet measures: Total assets were $29.01 million, stockholders’ equity was $25.62 million, and accumulated development-stage deficit was $83.17 million. No meaningful operating margin is available because there was no revenue.
Material changes versus prior comparable periods
- Second-quarter R&D expense rose 98.8% year over year; first-half R&D expense rose 209%, mainly due to VEN 309 Phase III trial costs and related development and manufacturing work.
- Second-quarter G&A expense fell 65.3% and first-half G&A fell 43.9%, primarily because stock-option and warrant expense was lower.
- First-half net loss increased from $9.68 million in 2011 to $15.64 million in 2012. Operating cash use also increased from $4.67 million to $13.03 million.
- Cash fell from $36.98 million at December 31, 2011 to $28.84 million at June 30, 2012. The company raised about $4.17 million net through at-the-market share sales in May and June.
Outlook, commentary, risks, and unusual items
- VEN 307 (diltiazem for anal fissures) met endpoints in a European Phase III trial. Ventrus planned a U.S. Phase III trial, targeting completion in the fourth quarter of 2012. It expected an FDA pre-NDA meeting in August 2012 and anticipated filing an NDA in the first quarter of 2013 if the FDA accepted the single European study as supporting the application; if two trials were required, filing was expected in the fourth quarter of 2013.
- VEN 309 (iferanserin for hemorrhoids) failed to meet endpoints in its Phase III trial. The company ceased development other than winding down the program and said it would prioritize VEN 307. Management expected VEN 309’s termination to reduce R&D expenses.
- Management estimated approximately $20 million to complete VEN 307 development and commercialization-related work, while noting estimates could change with trial progress, results, timing, and regulatory requirements. The filing’s detailed cost list gives the second Phase III trial cost as “$12,000;000”; the text does not provide a clear formatted value, though this appears to be a typographical error.
- Ventrus had about $95.5 million of securities capacity remaining under its shelf registration, including about $15.5 million available through its at-the-market program. Further capital may be needed; financing may be unavailable or dilutive, and collaboration or licensing could require surrendering rights.
- Key risks include clinical-trial failure or delay, FDA requiring additional studies, lack of approved products or revenue, uncertain access to financing, and stock-price volatility. The filing reported no material change to previously disclosed risk factors except the additions described in the report.
- Unusual items include the cessation of VEN 309 development following its Phase III failure and the resulting change in resource allocation. The company reported no off-balance-sheet arrangements and stated disclosure controls were effective, with no material second-quarter change in internal control over financial reporting.
Important facts for investors to verify
- Confirm the registrant identity: the filing is for Ventrus BioSciences, Inc., not Assembly Biosciences, Inc.
- Review subsequent FDA feedback on whether the European VEN 307 trial could support the NDA and whether additional U.S. Phase III trials were required.
- Verify VEN 307 U.S. trial timing, results, total development costs, and whether the stated cash runway remained achievable.
- Check the reported “$12,000;000” trial-cost figure against the original filing or subsequent disclosures.
- Assess future financing needs, use of the shelf and at-the-market capacity, and potential dilution.